# Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma

> **NCT03881501** · — · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 2 (estimated)

## Conditions studied

- Hepatocellular Carcinoma Non-resectable

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03881501
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-05
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03881501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03881501, "Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03881501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*